SecBot SecBot
PRESS-RELEASE ·Filed Nov 10, 2026

COAG

Hemab Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed6d 16h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor enrollment updates for the SOLARA Phase 3 trial and initial Phase 1 data for HMB-003 expected in mid-2027. Data presentations at ASH in December 2026 and EAHAD in February 2027 could provide catalysts.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$38.77
T+0 close · Nov 10, 2026 · via day close
Latest settled
+1.44%
T+1 · $39.33
Vs SPY
+0.13%
α at T+1
Next horizon
T+5
in 7h
  1. T+0 · Nov 10 $38.77entry
  2. T+1 · 6d ago +1.44%α +0.13% · $39.33
  3. T+4 · todayOpen
  4. T+5 · in 7h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Hemab Therapeutics reported a Q3 2026 net loss of $27.3M ($0.58 per share), wider than the $17.1M loss in Q3 2025, driven by increased R&D spending as clinical programs advanced. The company initiated a pivotal Phase 3 trial (SOLARA) for sutacimig in Glanzmann thrombasthenia and dosed the first participant in a Phase 1 trial for HMB-003 in heavy menstrual bleeding. Cash of $430.2M is expected to fund operations into 2029.

Key Financial Metrics

EPS
−$0.58

Key Facts

  • Net loss of $27.3M ($0.58 per share) for Q3 2026, vs $17.1M ($18.04 per share) in Q3 2025
  • Cash, cash equivalents and marketable securities totaled $430.2M as of Sep 30, 2026, down from $457.5M as of Jun 30, 2026
  • Initiated SOLARA, a pivotal Phase 3 trial of sutacimig in Glanzmann thrombasthenia (GT), the first pivotal trial of a subcutaneous prophylactic treatment in GT
  • Dosed first participant in Phase 1 trial of HMB-003 for heavy menstrual bleeding
  • First clinical data for sutacimig in Factor VII deficiency showed >50% shortening of prothrombin time in both participants
  • R&D expenses were $24.6M in Q3 2026, up from $14.6M in Q3 2025
  • G&A expenses were $5.1M in Q3 2026, up from $2.5M in Q3 2025

Financial Impact

Net loss increased by $10.2M YoY; cash burn of $27.3M in the quarter; cash runway into 2029

net losscash positionR&D expenses

Risk Factors

  • FDA recommended a randomized controlled design for SOLARA; single-arm design may complicate regulatory approval
  • No approved prophylactic treatments for GT; trial design and enrollment challenges in rare disease
  • Increasing operating losses and cash burn rate

Market Snapshot

Exchange
Nasdaq
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3399342

Track record

19 reports on COAG

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago Press Release Neutral 4/10 Viewing Entry $38.77 Now $39.06 +0.75% settles Nov 17
  2. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $42.81 to $39.06 Now $39.06 −8.76% ▼ −8.77% −7.08% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $49.02 to $40.86 Now $39.06 −20.32% ▼ −16.65% −19.24% vs SPY
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $45.09 to $39.33 Now $39.06 −13.37% ▼ −12.77% −11.86% vs SPY
  5. Sep 25, 20267w ago 3 Neutral 2/10 Entry $33.12 to $30.59 Now $39.06 +17.93% ▼ −7.64% −8.84% vs SPY
  6. Sep 17, 20268w ago Press Release Neutral 4/10 Entry $41.22 to $35.72 Now $39.06 −5.24% ▼ −13.34% −14.19% vs SPY
  7. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $49.87 to $52.44 Now $39.06 −21.68% ▲ +5.15% +5.56% vs SPY
  8. Jun 17, 202621w ago Insider Buy Neutral 2/10 Entry $29.24 to $27.72 Now $39.06 +33.58% ▼ −5.20% −3.53% vs SPY
  9. May 21, 202625w ago Press Release Neutral 5/10 Entry $26.30 to $28.50 Now $39.06 +48.52% ▲ +8.37% +6.52% vs SPY
  10. May 4, 202628w ago 8-K Neutral 4/10 Entry $25.00 to $25.90 Now $39.06 +56.24% ▲ +3.60% +1.62% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens Wed (9h 31m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026